Taking the red out of eosinophilic inflammation in COPD - 05/08/20
Doi : 10.1016/j.jaci.2020.05.028
Robert K. Bush, MD ⁎ 
Department of Medicine, Division of Allergy, Immunology, Pulmonary, Critical Care, University of Wisconsin School of Medicine and Public Health, Madison, Wis
∗Corresponding author: Robert K. Bush, MD, H6/918 CSC, 600 Highland Ave, Madison, WI 53792.H6/918 CSC600 Highland AveMadisonWI53792
Key words : Asthma-COPD overlap, benralizumab, biologics, COPD, eosinophils
Il testo completo di questo articolo è disponibile in PDF.
| Disclosure of potential conflicts of interest: R. K. Bush consults for UpToDate, serves as a section editor for Current Allergy Reports and Current Opinions in Allergy and Immunology, and is an associate editor for the Journal of Allergy and Clinical Immunology. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 2
P. 278-279 - Agosto 2020 Ritorno al numero
Articolo precedente
- Birth control medications decrease asthma incidence
- Dawn C. Newcomb
- Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
- Koa Hosoki, Abhijit Chakraborty, Sanjiv Sur
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?